IVONESCIMAB
UNII Y0O332CU66

Substance Identification & Data

This profile provides standardized clinical and technical data for Ivonescimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) Y0O332CU66.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2428381-53-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

Y0O332CU66

CAS Registry Number

2428381-53-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

IVONESCIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C184865

National Cancer Institute reference terminology for clinical and research data.

INN ID

11809

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

LM-231

Identifier assigned by the United States Adopted Names Council.

Substance Type

Ivonescimab

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Ivonescimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Ivonescimab

Common Names & Synonyms

IVONESCIMAB [USAN]

Immunoglobulin G1 [240-alanine,241-alanine], anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal AK112 γ1-chain) fusion protein with peptide linker (GGGS)4 fusion protein with immunoglobulin anti-(human programmed cell death protein 1) (human-Mus musculus heavy chain V-D-J region) fusion protein with peptide linker (GGGS)4 fusion protein with immunoglobulin anti-(human programmed cell death protein 1) (human-Mus musculus κ-chain V-J region), disulfide with human-Mus musculus monoclonal AK112 κ-chain, dimer

Ivonescimab [WHO-DD]

immunoglobulin G1-kappa_scFv, anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], each heavy chain being fused to a scFv anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279)], monoclonal antibody, tetravalent, bispecific; gamma1 heavy chain anti-VEGFA fused to scFv anti-PDCD1 (1-719) [gamma1 heavy chain anti-VEGFA (1-453) [VH (Homo sapiens IGHV3-30*02 (76.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*01, G1m17,1, G1v14 CH2 A1.3, A1.2 (CH1 K120 (220) (124-221), hinge 1-15 (222-236), CH2 L1.3>A (240), L1.2>A (241) (237-346), CH3 D12 (362), L14 (364) (347-451), CHS (452-453)) (124-453)] -20-mer tetrakis(tetraglycyl-seryl) linker (454-473) -scFv-VH-V-KAPPA anti-PDCD1 (474- 719) [VH (Homo sapiens IGHV3-23*04 (88.7%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (586), CDR-IMGT [8.8.11] (499-506.524-531.570-580)) (474-591) -20- mer tetrakis(tetraglycyl-seryl) linker (592-611) -V-KAPPA Musmus/Homsap (Mus musculus IGKV14-111*01 (86.3%) -IGKJ5*01 (100%)/Homo sapiens IGKV1- 16*01 (80.0%) -IGKJ2*01 (87.5%) Q120>A (711), CDR-IMGT [6.3.9] (638- 643.661-663.700-708)) (612-719)], (226-214')-disulfide with kappa light chain anti-VEGFA (1'-214') [V-KAPPA (Homo sapiens IGKV1-16*01 (88.4%) - IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (232-232'':235-235'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

ivonescimab [INN]